The most common frontline treatment for diffuse large B cell lymphoma (DLBCL) is cyclophosphamide, doxorubicin, vincristine sulfate, and prednisone (CHOP). However, approximately 1 in 3 patients relapse after CHOP, and alternative therapies are still needed.
According to Jason Westin, MD, the leader of the DLBCL research team at the University of Texas MD Anderson Cancer Center, the strategies for DLBCL treatment have not changed drastically since the mid 1970s. Additionally, more information is needed as to why patients relapse after CHOP.
For patients who are CHOP resistant, the standard of care is strong chemotherapy followed by an autologous stem cell transplant. However, according to Westin, more personalized and targeted therapies are needed.
In an interview with Targeted OncologyTM, Westin discussed the future of DLBCL treatment in both the frontline and later-line settings, along with current unmet clinical needs.
TARGETED ONCOLOGY: Can you give a background on current treatments in DLBCL?
WESTIN: DLBCL is the most common lymphoid cancer in adults, it's diagnosed in about 30,000 people each year in the US. And the treatments of that most common lymphoid cancer have been effectively stuck in the 1970s and the 1990s. We use a combination chemotherapy approach called CHOP, which was originally prescribed in 1976. We've changed a lot in life from 1976 to now, but we're still using this old combination chemotherapy in the curative setting for lymphoma. So obviously, new approaches are needed.
What does the current DLBCL treatment landscape?
Most patients are treated with the combination chemotherapy CHOP, and that cures approximately 2/3 of patients. It's a fairly effective standard therapy. However, at least 1 out of 3 people need additional treatments, and we don't do as well in the relapse setting as we'd like. So, we're constantly trying to innovate and improve that frontline setting and get beyond the 2/3 cure rate with initial treatments, and that will take a better understanding of why those 1/3 don't respond to CHOP, and a better understanding of the biology of what makes them resistant to treatments.
Do we know anything right now about the mechanisms of resistance to CHOP?
We know some, but I argue that we don't nearly know as much as we think we do. We understand the biology in the sense of understanding which mutation is present, or what type of gene signature. But often, the actual reason as to why a given patient doesn't respond to CHOP is very poorly understood. Patients that have the same biopsy, same genetic signature, some of those patients are cured and some of those patients are resistant. And it's difficult to predict prior to therapy which of those patients are resistant.
For patients that are resistant to CHOP, what options exist for them?
The standard of care for the past 20 years for those resistant to CHOP has been strong chemotherapy followed by an autologous stem cell transplant. Beyond the second line setting right now, there are a number of FDA approved agents for patients with relapsed BLBCL, and many of those FDA approved agents are being studied in combination CHOP and rituximab [Rituxan; R-CHOP].
What clinical needs are still unmet in this patient population?
The needs that are still unmet are finding more personalized therapies, specifically for those patients who are not cured with R-CHOP. But I would argue even in those patients who are currently cured with R-CHOP, that we don't want to use 1970s, chemotherapy in 2050. We want to be able to have personalized approaches and be able to move beyond effectively sledgehammer kind of blunt force instruments and use more precision medicine. So, we clearly need to do better urgently for the folks who are currently resistant or not responsive to chemotherapy. But I'd argue in the long run we need to do better across the board.
Do you see more aggressive approaches like autologous stem cell transplant and targeted therapies moving to the frontline setting in the future? Or do you think they'll remain a second- and third-line option?
I think that CAR T cells have the potential to move to the frontline for a subset of patients, for those that are not going to be responsive to our standard treatments. I think that's an approach that has merit, to try and use a powerful weapon at an earlier time point. I don't think stem cell transplant will do that. But I do think some of the other targeted therapies, the antibody drug conjugates, the bispecific antibodies, antibodies in combination with other immune therapies do potentially have a role to play in the frontline setting.
Where do you see the DLBCL space going in the next 5 to 10 years?
Well, I'd love to say things will be dramatically different. But we could have said that at any point over the last 20 years and would have been wrong. There are multiple ongoing studies looking at ways to improve the frontline setting. But innovation is more likely in the relapse space, which then filters up to the frontline space. And I think that the CAR T-cell studies showing potential advantages in the second line will change the landscape for patients who have relapsed after R-CHOP in the next 5 to 10 years to favor using CAR T-cell therapy. I think based on having that better cure fraction in the relapse space, more innovation may be possible in the frontline space. And so therefore doing studies that are not handcuffed to the 1970s chemotherapy for fear of not giving a patient the old curative therapy and missing a potential window for cure, I think that will allow us to do more innovative studies. I've done a handful of clinical trials using targeted therapy combinations prior to chemotherapy. And what we've shown in those studies is the response rates are very high. And patients tolerate it very well. And so that's still on a clinical trial stage. But it does show the potential that these targeted treatments can work better in newly diagnosed patients and potentially forego the need for chemotherapy.
I think the R-CHOP plus combination trial designs a failure. And I think that more innovative trial designs are needed. But clinical research still remains the best weapon we have to fight cancer in general and specifically DLBCL.
See the rest here:
Newer Agents for DLBCL Show Potential for Earlier Use in the Course of Treatment - Targeted Oncology
- Biology of stem cells: an overview - PMC - National Center for ... - March 26th, 2024
- Iron Limitation Preserves Youthfulness of Blood Stem Cells - Mirage News - March 13th, 2024
- Mini organs grown from stem cells of unborn babies for the first time in breakthrough - The Mirror - March 9th, 2024
- The Effect of Short-Term NAD3 Supplementation on Circulating Adult Stem Cells in Healthy Individuals Aged 40-70 ... - Cureus - March 7th, 2024
- University of Liverpool Spin-Out Emerges, Pioneering Novel Adult Stem Cell-Based Therapies - India Education Diary - March 7th, 2024
- Scientists have used cells from fluid drawn during pregnancy to grow mini lungs and other organs - Yahoo News Canada - March 6th, 2024
- Japan approves new stem cell-based Alzheimer's therapy By Proactive Investors - Investing.com Australia - January 20th, 2024
- Cyberstalking pits Harvard professor against PubPeer Retraction ... - Retraction Watch - December 5th, 2023
- 10 functional health predictions for 2024, according to a doctor and ... - 1330 WFIN - December 5th, 2023
- See the Brain Like Never Before in This Gorgeous Art - Scientific American - December 5th, 2023
- Geron Announces Publication in The Lancet of Results from the ... - BioSpace - December 5th, 2023
- Stem cell injections could be the key to curing MS - Freethink - December 3rd, 2023
- Jaypirca (pirtobrutinib) Now Approved by U.S. FDA for the ... - Investors | Eli Lilly and Company - December 3rd, 2023
- Comparative Efficacy and Safety of Four JAK Inhibitors for ... - HealthDay - December 3rd, 2023
- City lights up for Francis on Anthony Nolan's birthday - Liverpool Express - December 3rd, 2023
- NOT-AR-23-022: Request for Information on Themes for the NIAMS ... - National Institutes of Health (.gov) - December 3rd, 2023
- December 2023: Intramural Papers of the Month - Environmental Factor Newsletter - December 1st, 2023
- CNA Explains: What is cord blood banking and why do parents do it? - CNA - December 1st, 2023
- Regulation of myogenesis and adipogenesis by the electromagnetic ... - Nature.com - December 1st, 2023
- The effects of vitamin K on bone health - News-Medical.Net - December 1st, 2023
- Dr Hurwitz on Ongoing Investigations of the Use of CAR T-Cell ... - OncLive - December 1st, 2023
- Mitophagy in human health, ageing and disease - Nature.com - December 1st, 2023
- Adult Stem Cells - Stem Cells and the Future of Regenerative Medicine ... - November 29th, 2023
- Navigating The Regulatory Landscape Of Longevity Health Products ... - Mondaq News Alerts - November 29th, 2023
- MS breakthrough could lead to treatments that halt disease's ... - inews - November 29th, 2023
- Reprogramming tissue mechanically to promote wound healing - Phys.org - November 29th, 2023
- Latest Advances in Arthritis Diagnosis and Treatment at American ... - HealthDay - November 29th, 2023
- Sex-associated differences in frequencies and prognostic impact of ... - Nature.com - November 29th, 2023
- Hematologists Dive into the Current Treatment Landscape - OncLive - November 29th, 2023
- Team discovers protein crucial for B cell differentiation and antibodies - Phys.org - November 29th, 2023
- Science Talk - I survived cancer as a child and now I'm working to ... - The Institute of Cancer Research - November 29th, 2023
- First Edition: Nov. 29, 2023 - KFF Health News - November 29th, 2023
- Symptoms: Unilateral Hearing Loss and Tinnitus : The Hearing Journal - LWW Journals - November 29th, 2023
- Mitigation of sepsis-induced acute lung injury by BMSCs | IJN - Dove Medical Press - November 29th, 2023
- A Case of a Constricted Vessel: The Impact of Acute Myeloid ... - Cureus - November 29th, 2023
- Mum brushed off fatigue after having baby but fall sparked deadly diagnosis - The Mirror - November 29th, 2023
- How heritable is the epigenome? - Drug Discovery News - November 29th, 2023
- The Blueprint of Regeneration: Scientists Discover How to Turn Stem Cells Fate - Revyuh - November 27th, 2023
- BrainStorm Cell Therapeutics Announces In-Person Meeting with ... - Marketscreener.com - November 27th, 2023
- Stem Cell Therapy Developed in Korea Begins Treatment for ... - PharmiWeb.com - November 25th, 2023
- COVID-19 Pandemic's Adverse Effect on Bone Health in Young ... - HealthDay - November 25th, 2023
- Sickle cell breakthrough - The Indian Express - November 25th, 2023
- Wall thickness analysis method for judging the degree of lower ... - Nature.com - November 25th, 2023
- Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference - Yahoo Finance - November 23rd, 2023
- Disease Transmission and Diagnosis of Zika Virus - Cureus - November 23rd, 2023
- Gene-editing therapy for sickle cell earns conditional approval in UK - Sickle Cell Disease News - November 23rd, 2023
- Stem Cell Therapy Developed in Korea Begins Treatment for ... - Newswire - November 21st, 2023
- Efficacy of ADSC-CM in Patients with Telogen Effluvium | SCCAA - Dove Medical Press - November 21st, 2023
- BrainStorm Cell Therapeutics Announces In-Person Meeting with ... - PR Newswire - November 21st, 2023
- The Impact of CAR T Cell Therapy on Managing R/R LBCL - OncLive - November 21st, 2023
- Mansour bin Zayed witnesses inauguration of ADSCC Bone Marrow Transplant & Cellular Therapy Congress 2023 - ZAWYA - November 21st, 2023
- Listeria: Who is most susceptible? What are the Symptoms? What ... - Food Poison Journal - November 21st, 2023
- Scope Of Issued Patents May Be Limited By Prosecution Estoppel ... - Mondaq News Alerts - November 21st, 2023
- Qrons Announces the Addition of Professor Shiri Navon-Venezia to ... - StreetInsider.com - November 21st, 2023
- Financially strapped Athersys raises $10.4M - cleveland.com - November 19th, 2023
- From the India Today archives (2010) | How stem cells can save your life - India Today - November 19th, 2023
- Inactivation of the tumor suppressor gene Apc synergizes with H ... - Science - November 19th, 2023
- The Origins of Multiple Myeloma and Why it Matters - HealthTree For AML - Acute Myeloid Leukemia - November 19th, 2023
- Treatment Considerations With TROP2-Targeted Therapy - OncLive - November 19th, 2023
- Athersys narrows loss, raises $10.4 million during third quarter to ... - The Business Journals - November 17th, 2023
- Who was Dolly the Sheep and what happened to her? The story of ... - BBC Countryfile Magazine - November 17th, 2023
- UK first to approve CRISPR treatment for diseases: what you need to ... - Nature.com - November 17th, 2023
- 1st sickle cell patient to be given therapy restoring fetal hemoglobin - Sickle Cell Disease News - November 15th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates - Century - Benzinga - November 13th, 2023
- Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer - Yahoo Finance - November 11th, 2023
- Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in... - November 11th, 2023
- AAO 2023: Paul Runge and his ROP treatments in the Ukraine - Modern Retina - November 11th, 2023
- The Evolutionary Reasons We Are Drawn To Horror Movies and ... - Slashdot - November 11th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results ... - GlobeNewswire - November 11th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results ... - StreetInsider.com - November 9th, 2023
- NYU Langone Health Performs World's First Whole-Eye & Partial ... - NYU Langone Health - November 9th, 2023
- BrainStorm to Announce Third Quarter 2023 Financial Results and ... - BioSpace - November 9th, 2023
- Can we cut cost and pain of IVF? Start-up CEO tries out own ... - Genetic Literacy Project - November 9th, 2023
- Jasper Therapeutics Reports Third Quarter 2023 Financial Results ... - BioSpace - November 9th, 2023
- Impaired neural stress resistance and loss of REST in bipolar ... - Nature.com - November 9th, 2023
- Functional genomics and systems biology in human neuroscience - Nature.com - November 9th, 2023
- Trial launched to test CAR T-cell therapy in dogs diagnosed with ... - EurekAlert - November 9th, 2023
- The-Gut's-Lasting-Impact-on-Severe-COVID-19-Immune-Response - Infectious Disease Special Edition - November 9th, 2023
- Emerging Cure for Sickle Cell on its Way to FDA Approval, Carries ... - Dallasweekly - November 7th, 2023
- The science works, but will we pay for it? - Irish Medical Times - November 7th, 2023
Recent Comments